Progenics Pharmaceuticals (NASDAQ:PGNX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.09, Morningstar.com reports. Progenics Pharmaceuticals had a negative return on equity of 94.45% and a negative net margin of 341.41%. The business had revenue of $5.32 million during the quarter, compared to the consensus estimate of $4.14 million.
PGNX stock traded down $0.23 during trading on Friday, reaching $5.41. 743,800 shares of the stock traded hands, compared to its average volume of 1,375,316. Progenics Pharmaceuticals has a 52-week low of $4.68 and a 52-week high of $9.42. The company has a current ratio of 6.34, a quick ratio of 6.34 and a debt-to-equity ratio of 0.68. The company has a market cap of $474.28 million, a PE ratio of -6.01 and a beta of 2.81.
A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 4th. ValuEngine raised Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 30th. Jefferies Financial Group reissued a “buy” rating and set a $13.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, August 1st. BidaskClub downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 5th. Finally, Needham & Company LLC reissued a “strong-buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $11.69.
ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2018/11/10/progenics-pharmaceuticals-pgnx-posts-earnings-results-beats-expectations-by-0-09-eps.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Featured Article: Stock Selection – What is cash flow?
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.